L. Becker Hewes - 31 May 2024 Form 4 Insider Report for Blueprint Medicines Corp (BPMC)

Role
CHIEF MEDICAL OFFICER
Signature
/s/ Melissa Masse
Issuer symbol
BPMC
Transactions as of
31 May 2024
Net transactions value
-$2,674,682
Form type
4
Filing time
04 Jun 2024, 16:00:06 UTC
Previous filing
11 Mar 2024
Next filing
06 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BPMC Common Stock Options Exercise $700,356 +10,573 +23% $66.24 56,854 31 May 2024 Direct F1
transaction BPMC Common Stock Options Exercise $514,084 +8,385 +15% $61.31 65,239 31 May 2024 Direct F1
transaction BPMC Common Stock Options Exercise $247,206 +5,729 +8.8% $43.15 70,968 31 May 2024 Direct F1
transaction BPMC Common Stock Sale $395,954 -3,671 -5.2% $107.86 67,297 31 May 2024 Direct F1, F2
transaction BPMC Common Stock Sale $339,842 -3,191 -4.7% $106.50 64,106 31 May 2024 Direct F1, F3
transaction BPMC Common Stock Sale $2,211,852 -20,904 -33% $105.81 43,202 31 May 2024 Direct F1, F4
transaction BPMC Common Stock Sale $664,832 -6,342 -15% $104.83 36,860 31 May 2024 Direct F1, F5
transaction BPMC Common Stock Sale $316,204 -2,971 -8.1% $106.43 33,889 03 Jun 2024 Direct F1
transaction BPMC Common Stock Sale $207,645 -1,951 -5.8% $106.43 31,938 03 Jun 2024 Direct F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BPMC Stock Options (Right to Buy) Options Exercise $0 -10,573 -44% $0.000000 13,490 31 May 2024 Common Stock 10,573 $66.24 Direct F1, F7
transaction BPMC Stock Options (Right to Buy) Options Exercise $0 -8,385 -48% $0.000000 9,115 31 May 2024 Common Stock 8,385 $61.31 Direct F1, F8
transaction BPMC Stock Options (Right to Buy) Options Exercise $0 -5,729 -23% $0.000000 19,271 31 May 2024 Common Stock 5,729 $43.15 Direct F1, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Effected pursuant to a trading plan adopted on March 1, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $107.50 to $108.31 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) through (5) in this form 4.
F3 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $106.24 to $107.20 per share.
F4 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $105.22 to $106.20 per share.
F5 The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $104.43 to $105.20 per share.
F6 The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
F7 This option was granted on June 1, 2020. This option vested with respect to 25% of the shares underlying the option on June 1, 2021 and as to an additional 1/48th of the shares underlying the option each month thereafter.
F8 This option was granted on March 1, 2022. This option vested with respect to 1/48th of the shares underlying the option on April 1, 2022 and as to an additional 1/48th of the shares underlying the option each month thereafter.
F9 This option was granted on March 1, 2023. This option vested with respect to 1/48th of the shares underlying the option on April 1, 2023 and as to an additional 1/48th of the shares underlying the option each month thereafter.